InterMune
will collaborate with
National Jewish Health investigators to help further the research of inherited genetic factors that may play a role in
idiopathic pulmonary fibrosis (IPF).
InterMune will provide researchers at National Jewish Health with access to DNA collected from patients who participated in the company’s Phase III trials in IPF for both pirfenidone and actimmune (interferon gamma-1b). The database includes DNA from approximately 1,500 IPF patients.